View Older Stories View More Recent Stories

Dec 2, 2018 03:45PM Pfizer Presents Positive 26-Week Data For PF-05280586, A Potential Biosimilar To Rituximab, At The American Society Of Hematology Annual Meeting
Nov 30, 2018 10:01AM Pfizer (PFE) Reaches Global Agreement with AbbVie (ABBV) on Adalimumab Biosimilar
Nov 30, 2018 10:00AM Pfizer Reaches a Global Agreement with AbbVie
Nov 27, 2018 03:02PM Pfizer (PFE) Granted Six Months Pediatric Exclusivity for LYRICA
Nov 27, 2018 03:01PM Pfizer Receives Six Months Pediatric Exclusivity for LYRICA® (pregabalin)
Nov 21, 2018 01:42PM Pfizer (PFE) Announces FDA Approval of DAURISMO
Nov 21, 2018 01:40PM U.S. FDA Approves DAURISMO™ (glasdegib) for Adult Patients with Newly-Diagnosed Acute Myeloid Leukemia (AML) for Whom Intensive Chemotherapy is Not an Option
Nov 19, 2018 07:23AM Pfizer (PFE) and Merck KGaA, Darmstadt, Germany Report Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Nov 19, 2018 07:12AM Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Nov 2, 2018 04:42PM U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC
Oct 29, 2018 02:15AM Pfizer Announces Clinical Development Agreement with Novartis to Advance the Treatment of NASH
Oct 24, 2018 05:51AM Pfizer (PFE), Eli Lilly and Co. (LLY) Report Complete Results from Phase 3 Study of Tanezumab Showing Significant Improvement in Pain & Function in Osteoarthritis Patients
Oct 23, 2018 06:40PM Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients
Oct 23, 2018 08:40AM Bain Capital and Pfizer (PFE) Create Cerevel Therapeutics
Oct 23, 2018 08:30AM Bain Capital and Pfizer Create Cerevel Therapeutics, New CNS Company
Oct 22, 2018 06:09AM Pfizer (PFE) Reports OS Data from PALOMA-3 Trial of IBRANCE (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer
Oct 20, 2018 10:30AM Pfizer Presents Overall Survival Data From PALOMA-3 Trial of IBRANCE® (palbociclib) in Patients With HR+, HER2- Metastatic Breast Cancer
Oct 18, 2018 07:01AM Merck (MRK) Reports Significant Improved OS & PFS Data from Pivotal Phase 3 KEYNOTE-426 Trial Investigating KEYTRUDA (pembrolizumab) in Combination with Pfizer’s (PFE) Inlyta (axitinib)
Oct 1, 2018 06:46AM Pfizer (PFE) Elected Dr. Albert Bourla to Succeed Ian Read as CEO Effective January 1; Ian Read will Transition to Executive Chairman
Oct 1, 2018 06:45AM Pfizer Announces CEO Succession
Sep 27, 2018 05:42PM Pfizer (PFE) Announces U.S. FDA Approval of VIZIMPRO for First-Line Treatment of Patients with EGFR-Mutated Metastatic NSCLC
Sep 27, 2018 05:41PM U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
Sep 27, 2018 01:09PM Pfizer Declares 34-Cent Fourth-Quarter 2018 Dividend
Sep 20, 2018 08:05AM Pfizer (PFE) Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for Prevention of Invasive Disease and Pneumonia in Adults
Sep 20, 2018 08:00AM Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
Sep 18, 2018 09:04AM Pfizer (PFE) Says New Sub-group Analyses from Tafamidis Phase 3 ATTR-ACT Study Presented at HFSA
Sep 18, 2018 09:00AM New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting
Sep 18, 2018 09:00AM New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting
Sep 18, 2018 09:00AM New Sub-group Analyses from the Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Presented at 2018 HFSA Annual Scientific Meeting
Sep 17, 2018 05:50AM Pfizer (PFE) Announces Positive Phase 2 Data in Alopecia Areata at 2018 EADV Congress
Sep 15, 2018 02:00AM Pfizer Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at the 27th European Academy of Dermatology and Venereology (EADV) Congress
Sep 11, 2018 08:28AM BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Significantly Improved Progression-Free Survival in Previously Untreated Patients With Advanced Renal Cell Carcinoma in Phase III Study
Sep 5, 2018 08:51AM Pfizer (PFE) Gains FDA Breakthrough Therapy Designation for PF-06651600
Sep 5, 2018 08:50AM Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata
Aug 30, 2018 08:00AM Pfizer (PFE) Terminates Domagrozumab Clinical Studies for the Treatment of DMD
Aug 30, 2018 08:00AM Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne Muscular Dystrophy
Aug 27, 2018 05:40AM Pfizer (PFE) Reports Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results at ESC Congress 2018
Aug 27, 2018 05:21AM Tafamidis Phase 3 Transthyretin Amyloid Cardiomyopathy (ATTR-ACT) Study Results Presented as Late-Breaking Data at the ESC Congress 2018
Aug 22, 2018 06:09AM Exact Sciences (EXAS) Announces U.S. Promotional Agreement with Pfizer (PFE) for Cologuard
Aug 22, 2018 06:00AM Exact Sciences and Pfizer Enter into U.S. Promotion Agreement for Cologuard®
Aug 16, 2018 06:08AM Pfizer (PFE) Reports Collaboration Agreement with BioNTech for Development mRNA-based Vaccines for Prevention of Influenza
Aug 16, 2018 06:00AM BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
Aug 16, 2018 01:00AM BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
Aug 1, 2018 06:30AM Pfizer (PFE) Reports Marketing Authorization in European Union from Euro Commission for Moderately to Severely Active Ulcerative Colitis
Aug 1, 2018 01:00AM XELJANZ® (tofacitinib citrate) Receives Marketing Authorization in the European Union for Moderately to Severely Active Ulcerative Colitis
Jul 31, 2018 06:10AM Pfizer (PFE) Announces EU Approval of Biosimilar TRAZIMERA
Jul 31, 2018 06:00AM Pfizer Receives European Approval for Oncology Biosimilar, TRAZIMERA™ (trastuzumab)
Jul 24, 2018 01:31PM Pfizer (PFE) to Build Sterile Injectable Facility in Michigan
Jul 24, 2018 01:30PM Pfizer to Build Cutting-Edge Sterile Injectable Facility in Michigan, Investing Nearly Half a Billion Dollars in U.S. Manufacturing, Creating More than 450 Jobs
Jul 20, 2018 04:26PM Pfizer (PFE) Announces FDA Approves for its Neupogen Biosimilar NIVESTYM
View More Recent Stories View Older Stories